Metabolisches Syndrom und Prostatakarzinom

Abstract

The relationship between metabolic syndrome (MS) and prostate cancer (PCA) is highly complex and harbors multiple facets not least because MS is not a single entity but represents a poorly defined inhomogeneous mixture of different diseases and conditions. Although numerous studies suggest a correlation between MS or components of MS and the development of prostate cancer, current evidence cannot be considered convincing. While diabetes appears to be inversely related to PCA, increased serum levels of triglycerides, cholesterol and insulin-like growth factor 1 (IGF-1) may be predictive for high grade disease. Further studies suggested that MS and high serum insulin levels are independent predictors of an unfavorable prognosis in patients with metastatic PCA. Early detection and improved therapeutic options have dramatically prolonged the course of the disease in advanced PCA through the last decades. As a consequence, development of MS in patients undergoing hormone therapy along with the cardiovascular risks has gained increasing relevance. Based on this evolution prevention, early detection and sustainable therapy represent an important clinical challenge to modern urologists active in urooncology.

Resistin Activates p65 Pathway and Reduces Glycogen Content through Keratin 8

“…Studies on keratin 8 have shown that it is an essential member of the keratin family, which plays an important role in glucose metabolism [9,11]. Although problems with the uptake of glucose and its metabolites in hepatocytes are mainly attributed to chronic insulin-related disease, there is also evidence supporting a correlation between diabetes and various malignant tumors [12][13][14][15]. A similar correlation exists between glycogen storage disease and liver cell abnormality.…”

Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study

“…Non-interventional study on effectiveness and tolerability and on the influence of anamnestic factors”) is an open-label, multi-centre, non-interventional German cohort study of Leuprone HEXAL in routine clinical practice. This study was designed to extend existing knowledge on the efficacy and tolerability of leuprorelin solid implant in men with PCa and to explore the influence of patient and lifestyle factors on disease course [4, 7-9]. This manuscript also compares the real-world clinical use for LHRH agonists in a contemporary patient cohort with guideline-recommended indications.…”